A Study to Evaluate the Safety and Effect of STC314 Injection Continuous Infusion in Subjects With Acute Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome Clinical Trial

Official title:

A Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Continuous Intravenous Infusion of STC314 Injection in Chinese Patients With Acute Respiratory Distress Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05000671
• Other study ID #: GPHIP-0103
• Status: Recruiting
• Phase: Phase 1
• Start date: July 28, 2021
• Est. completion date: December 2022

Study information

• Verified date: December 2021
• Source: Grand Medical Pty Ltd.
• Contact: James Pang, PhD
• Phone: +61 466555916
• Email: jpang[@]grandpharma.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a Randomized, Double-blinded, Placebo-controlled Phase Ib Study to Evaluate the Safety, Tolerability and Pharmacokinetics of STC314 Injection Administered as Continuous Intravenous Infusion in Chinese Patients with ARDS (Acute Respiratory Distress Syndrome).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 16
• Est. completion date: December 2022
• Est. primary completion date: December 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. 18 = age = 70 years, male or female;

2. Voluntarily participate in the study and sign the informed consent form;

3. Diagnosis of ARDS for no more than 48 hours (starting at the time of diagnosis recorded in the medical record);

4. The following 2012 Berlin definition criteria for mild to moderate ARDS were met:

1. From known clinical impairment and new or worsening of respiratory symptoms to fulfillment of diagnostic criteria is less than 7 days(inclusive).

2. Chest imaging suggests bilateral infiltrates. The effusion, lobar/atelectasis, or nodules cannot completely explain the phenomenon.

3. Respiratory failure cannot be completely explained by heart failure or fluid overload;

4. When PEEP or CPAP =5 cm H2O, 100 mmHg=PaO2/FiO2=300 mmHg;

5. Male subjects agree to use an effective contraceptive method from the start of the study until 7 days after the end of treatment; Female subjects of childbearing age agree to use an effective contraceptive method from the start of the study until 3 months after the end of treatment.

Exclusion Criteria:

1. Positive serum pregnancy test before dosing for women of childbearing potential, pregnant women, or lactating women;

2. Terminal phase of chronic disease with an expected survival of no more than 6 months;

3. Combined with one of the following chronic organ damage or immunosuppressive diseases:

1. Heart: New York Heart Association functional class IV;

2. Lung: severe lung disease, including pulmonary hypertension, oxygen therapy or ventilator dependence for more than one month cumulatively within the first six months of screening, end-stage lung disease, or severe exercise limitation caused by chest wall malformations;

3. Kidney: ongoing long-term dialysis treatment;

4. Liver: biopsy confirmed cirrhosis and portal hypertension, or previous upper gastrointestinal bleeding caused by portal hypertension; Liver failure, hepatic encephalopathy, or hepatic coma;

5. Immunosuppression: with lymphoma, leukemia or acquired immunodeficiency; Received anti-tumor chemotherapy in the last 3 months, or ongoing immunosuppressive therapy due to organ transplantation, immune diseases, etc.; Has undergone allogeneic bone marrow transplantation or hematopoietic stem cell transplantation; Steroid hormone therapy in the last 3 months (equivalent to > 0.5 mg/kg/day prednisone continued 1 month);

4. History of one of the following within 4 weeks prior to screening:

1. Acute pulmonary embolism;

2. Cardiac arrest;

3. Acute myocardial infarction;

5. eGFR < 60 mL/min/BSA (calculated using CG formula);

6. ALT > 5 x ULN, or total bilirubin > 2 x ULN;

7. Severe anemia (hemoglobin < 7.0 g/dL);

8. Absolute neutrophil count < 1500/µL;

9. Platelet count < 50,000/µL;

10. aPTT > 1.5 × ULN;

11. Active bleeding that cannot be effectively controlled;

12. The subject required therapeutic doses of heparin or was taking anticoagulants;

13. ARDS caused by direct lung injury due to physical or chemical causes;

14. Severe or greater burns: the overall surface area of burns exceeds 30% or the III degree burn area exceeds 10%; or the total area is less than 30%, but the general condition is severe or has shock, combined injury, respiratory tract burn;

15. Allergic to the active ingredients or excipients of the study drug;

16. Subjects have participated in other clinical studies (other than those who have not received intervention) or are participating in other experimental treatments within 1 month prior to screening;

17. In the opinion of the investigator, the subject could not benefit from the study or was not suitable for participation in the study.

Related Conditions & MeSH terms

• Acute Lung Injury
• Acute Respiratory Distress Syndrome
• Respiratory Distress Syndrome
• Respiratory Distress Syndrome, Newborn
• Syndrome

Intervention

Drug:
• STC314 injection or Placebo(rate=58.3 mg/hr)
To receive continuous infusion of STC314/Placebo injection at rate 58.3mg/hr up to 3 days (72hours). Also to receive appropriate standard of care.
• STC314 injection or Placebo(rate=87.5 mg/hr)
To receive continuous infusion of STC314/Placebo injection at rate 87.5mg/hr up to 3 days (72hours). Also to receive appropriate standard of care.

Locations

Country	Name	City	State
China	Xiangya Hospital Central South University	Changsha	Hunan
China	Zhongda Hospital Southeast University	Nanjing	Jiangsu
China	The Fourth Hospital of Hebei Medical University	Shijiazhuang	Hebei
China	Wuhan Jinyintan Hospital	Wuhan	Hubei
China	Wuhan Union Hospital	Wuhan	Hubei

Sponsors (2)

Lead Sponsor	Collaborator
Grand Medical Pty Ltd.	Grand Pharmaceutical (China) Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	As an exploratory objective, the change in biomarkers from baseline following STC314 injection treatment in subjects with Acute Respiratory Distress Syndrome will be evaluated.	Change of the level of Histone in plasma after dosing	Through 0 to144 hours after the start of treatment
Other	As an exploratory objective, the change in biomarkers from baseline following STC314 injection treatment in subjects with Acute Respiratory Distress Syndrome will be evaluated.	Change of the level of Neutrophil extracellular traps(NETs)-related variables in plasma after dosing [myelinated Oxidase (MPO), citrullinated histone H3 (CitH3), circular free DNA (cfDNA)]	Through 0 to144 hours after the start of treatment
Other	As an exploratory objective, the change in biomarkers from baseline following STC314 injection treatment in subjects with Acute Respiratory Distress Syndrome will be evaluated.	Change of the level of inflammatory factor interleukin-6 (IL-6) after dosing	Through 0 to144 hours after the start of treatment
Primary	To evaluate the safety of STC314 injection in patients with ARDS.	The incidence of adverse event (AE) and serious adverse event (SAE);	Within 28 days after the start of treatment
Primary	To evaluate the safety of STC314 injection in patients with ARDS.	Rates of Treatment Discontinuation Due to Adverse Events;	Within 28 days after the start of treatment
Primary	To evaluate the pharmacokinetic of STC314 injection in patients with ARDS.	maximum concentration (Cmax)	Through 0 to144 hours after the start of treatment
Primary	To evaluate the pharmacokinetic of STC314 injection in patients with ARDS.	area under the plasma concentration-time curve (AUC0-t, AUC0-inf)	Through 0 to144 hours after the start of treatment
Primary	To evaluate the pharmacokinetic of STC314 injection in patients with ARDS.	time to peak (Tmax)	Through 0 to144 hours after the start of treatment
Primary	To evaluate the pharmacokinetic of STC314 injection in patients with ARDS.	elimination half Decay (t1/2)	Through 0 to144 hours after the start of treatment
Primary	To evaluate the pharmacokinetic of STC314 injection in patients with ARDS.	elimination rate constant(Kel)	Through 0 to144 hours after the start of treatment
Primary	To evaluate the pharmacokinetic of STC314 injection in patients with ARDS.	clearance (CL)	Through 0 to144 hours after the start of treatment
Secondary	To evaluate the efficacy of STC314 injection in patients with ARDS.	Changes of the value of blood lactate from baseline after dosing	Within 28 days after the start of treatment
Secondary	To evaluate the efficacy of STC314 injection in patients with ARDS.	Change of Oxygenation Index (PaO2/FiO2) from baseline after dosing	Within 28 days after the start of treatment
Secondary	To evaluate the efficacy of STC314 injection in patients with ARDS.	Change of Murray Lung Injury Score from baseline.(range 0-4, higher score means more severe lung injury)	Within 28 days after the start of treatment
Secondary	To evaluate the efficacy of STC314 injection in patients with ARDS.	Change of the value of serum creatinine from baseline after dosing	Within 28 days after the start of treatment
Secondary	To evaluate the efficacy of STC314 injection in patients with ARDS.	Change of the value of bilirubin from baseline after dosing	Within 28 days after the start of treatment
Secondary	To evaluate the efficacy of STC314 injection in patients with ARDS.	Change of the value of Alanine Transaminase(ALT) from baseline after dosing	Within 28 days after the start of treatment
Secondary	To evaluate the efficacy of STC314 injection in patients with ARDS.	Change of Sequential Organ Failure Assessment score from baseline after dosing.(range 0-4, higher score means a worse prognosis)	Within 28 days after the start of treatment
Secondary	To evaluate the efficacy of STC314 injection in patients with ARDS.	all-cause mortality within 28 days	Within 28 days after the start of treatment
Secondary	To evaluate the efficacy of STC314 injection in patients with ARDS.	Ventilator-free survival time within 28 days	Within 28 days after the start of treatment
Secondary	To evaluate the efficacy of STC314 injection in patients with ARDS.	Hospitalization time within 28 days	Within 28 days after the start of treatment
Secondary	To evaluate the efficacy of STC314 injection in patients with ARDS.	length of ICU stay within 28 days	Within 28 days after the start of treatment